Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy
- 43 Downloads
Cabergoline (CAB), a new long-acting ergoline derivative, was shown to be very effective in reducing PRL levels in normal volunteers and in hyperprolactinemic patients. We evaluated the hormonal changes after discontinuation of long-term therapy with CAB as well as the safety of drug exposure during pregnancy both for mothers and babies. We therefore studied 48 patients (47 females and one male) with pathological hyperprolactinaemia (mean±SE, 117.2±15.2; median 73.2 µg/l), treated for 1–82 months (mean±SE, 28.3±3; median 18). After long-term treatment, CAB was withdrawn in 11 patients and PRL levels were persistently normal for almost 15 days and significantly lower (p <0.05) than basal at 30, 45, 60, 90, 120 days. Three patients had normal PRL levels still at 45 days after treatment discontinuation. Nine patients became pregnant after 1–37 months (mean 12.4) of therapy. In two patients the pregnancy was interrupted spontaneously in one case and voluntarily in the other. In all but one patients, after delivery or three-month breast feeding, PRL levels trended towards reduction. In two cases (one with microadenoma and one with idiopathic hyperprolactinaemia) PRL remained in the normal levels for 1–3 years after delivery. In conclusion CAB is able to inhibit plasma PRL levels for long time (up to 120 days) after withdrawal in patients with pathological hyperprolactinaemia treated with long-term therapy.
Key-wordsHyperprolactinaemia therapy cabergoline dopaminergic drugs pregnancy
Unable to display preview. Download preview PDF.
- 2.Melis G.B., Gambacciani M., Paoletti A.M., Beneventi F., Mais V., Baroldi P., Fioretti P. Dose-related prolactin inhibitory effects of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women. J. Clin. Endocrinol. Metab. 65: 541, 1987.PubMedCrossRefGoogle Scholar
- 4.Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 69: 725, 1989.PubMedCrossRefGoogle Scholar
- 6.Webster J., Piscitelli G., Polli A., Dalberto A., Farsetti L., Ferrari C., Fioretti P., Giordano G., L’Hermite M., Ciccarelli E., Crosignani P.G., De Cecco L., Fadini R., Faglia G., Flamigni C., Tamburrano G., Ismail I., Scanion M.F. (European multicentre CAB study group). The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin. Endocrinol. 39: 323, 1993.CrossRefGoogle Scholar
- 7.Ferrari C., Paracchi A., Mattei M., de Vincentiis S., D’Alberton A., Crosignani P.G. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 126: 489, 1992.Google Scholar
- 9.Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O. and the bromocriptine study group. Bromocriptine as primary therapy for PRL-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.PubMedCrossRefGoogle Scholar
- 12.Di Salle E., Ornati G., Briatico G. FCE 21336, a new ergoline derivative with long-acting lowering effect on prolactin secretion in rats. (Abstract). J. Endocrinol. Invest. 6(Suppl 1): 6, 1982.Google Scholar
- 14.Di Salle E., Ornati G., Giudici D. A comparison of the in vivo and in vitro duration of prolactin lowering effect in rats of FCE 21336, pergolide and bromocriptine (Abstract). J. Endocrinol. Invest. 7(Suppl 1): 32, 1984.Google Scholar